SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Fundamental Analysis & Valuation

FRA:1SXP • DE000A3ENQ51

Current stock price

13.56 EUR
0 (0%)
Last:

This 1SXP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. 1SXP.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 1SXP was profitable.
  • 1SXP had a positive operating cash flow in the past year.
  • 1SXP had positive earnings in each of the past 5 years.
  • In the past 5 years 1SXP always reported a positive cash flow from operatings.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • 1SXP has a better Return On Assets (9.26%) than 89.47% of its industry peers.
  • With an excellent Return On Equity value of 16.21%, 1SXP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
  • 1SXP has a Return On Invested Capital of 12.84%. This is amongst the best in the industry. 1SXP outperforms 89.47% of its industry peers.
  • 1SXP had an Average Return On Invested Capital over the past 3 years of 14.59%. This is significantly above the industry average of 9.20%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • 1SXP has a Profit Margin of 15.13%. This is amongst the best in the industry. 1SXP outperforms 84.21% of its industry peers.
  • 1SXP's Profit Margin has improved in the last couple of years.
  • The Operating Margin of 1SXP (19.08%) is better than 73.68% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 33.68%, 1SXP perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
  • 1SXP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1SXP.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
  • Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
  • Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
  • Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • The Debt to FCF ratio of 1SXP is 7.05, which is on the high side as it means it would take 1SXP, 7.05 years of fcf income to pay off all of its debts.
  • 1SXP has a Debt to FCF ratio (7.05) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that 1SXP is not too dependend on debt financing.
  • 1SXP has a Debt to Equity ratio of 0.08. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.42
WACC9.06%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.58. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP's Current ratio of 1.58 is fine compared to the rest of the industry. 1SXP outperforms 63.16% of its industry peers.
  • A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.17, 1SXP is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 1SXP.DE Growth Analysis

3.1 Past

  • 1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
  • The Earnings Per Share has been growing by 13.78% on average over the past years. This is quite good.
  • The Revenue has been growing slightly by 4.39% in the past year.
  • 1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.01% on average per year.
  • The Revenue is expected to grow by 5.75% on average over the next years.
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. 1SXP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.98, the valuation of 1SXP can be described as correct.
  • 1SXP's Price/Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 89.47% of the companies in the same industry.
  • 1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.71.
  • Based on the Price/Forward Earnings ratio of 12.43, the valuation of 1SXP can be described as correct.
  • 1SXP's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 94.74% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, 1SXP is valued a bit cheaper.
Industry RankSector Rank
PE 13.98
Fwd PE 12.43
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 89.47% of the companies listed in the same industry.
  • 1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 68.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF 171.95
EV/EBITDA 7.66
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The excellent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.01
EPS Next 2Y6.04%
EPS Next 3Y8.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 1SXP.DE Dividend Analysis

5.1 Amount

  • 1SXP has a Yearly Dividend Yield of 1.33%. Purely for dividend investing, there may be better candidates out there.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 94.74% of the companies in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.91, 1SXP is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.33%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 1SXP pays out 15.99% of its income as dividend. This is a sustainable payout ratio.
DP15.99%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1SXP.DE Fundamentals: All Metrics, Ratios and Statistics

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (3/16/2026, 9:01:20 AM)

13.56

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners20.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.04B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts76.84
Price Target19.93 (46.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.33%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.13%
PT rev (3m)-30.29%
EPS NQ rev (1m)2.59%
EPS NQ rev (3m)-11.54%
EPS NY rev (1m)-4.55%
EPS NY rev (3m)-17.17%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)-1.81%
Revenue NY rev (3m)-5.95%
Valuation
Industry RankSector Rank
PE 13.98
Fwd PE 12.43
P/S 2.05
P/FCF 171.95
P/OCF 12.85
P/B 2.2
P/tB 2.27
EV/EBITDA 7.66
EPS(TTM)0.97
EY7.15%
EPS(NY)1.09
Fwd EY8.04%
FCF(TTM)0.08
FCFY0.58%
OCF(TTM)1.06
OCFY7.78%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)N/A
PEG (5Y)1.01
Graham Number11.61
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC9.06%
ROIC/WACC1.42
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.81%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 5 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to decline by -1.71% in the next year.